

RATIONALE

Pituitary neuroendocrine tumour (Pit-NET) represents a complex disease. The clinical manifestations of Pit-NETs are multiple and heterogeneous, according to the ability of secreting different hormones or pro-hormones and of invading the neighbouring anatomical structures, such as the same pituitary gland, the optical chiasm, the cavernous sinus, the bone, the third ventricle and the ventricular system.

In the most recent years, a better definition of these neoplasia was researched in order to identify biomarkers able to predict the natural history of Pit-NET and their responsiveness to the different treatments.

Until now, the classifications of the neoplasms arising from adeno-hypophysial cells have been misleading because of their poor reproducibility and their weak ability in predicting the aggressiveness, the prognosis, and the outcome of these neoplasia. The 2004 WHO classification distinguished pituitary adenoma in typical and atypical ones according to the detection of mitoses and according to the expression of Ki-67 or p53. The 2004 WHO classification however failed in identifying pituitary tumours refractory to medical, surgical or radiation therapies or able to regrowth or to metastasize. Similarly, the new 2017 WHO classification lacks in defining the prognosis of pituitary neoplasia. Invasive, recurrent and proliferative pituitary neoplasia cause significant morbidity, in particular in cases of persistence hormonal hyper-secretion. Both long term hormonal hyper-secretion and hypopituitarism, in absence of an adequate hormonal replacement therapy, are associated to increased morbidity and mortality for their systemic complications.

Therefore, recently, pituitary adenomas were recognised as neuroendocrine tumors (NETs). This new terminology of pituitary neuroendocrine tumor (PitNET) reflects better the potential for aggressiveness and malignant behaviour and of these neoplasia. On this basis, in the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNET, in order to predict the clinical behaviour of these neoplasia. The current event, has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNet affected patients.

The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease (2019) - Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome.

DIRECTOR Prof. ALFREDO PONTECORVI
Professor of Endocrinology
Fondazione Policlinico Universitario A. Gemelli
Università Cattolica del Sacro Cuore, Rome

RESPONSABILE SCIENTIFICO

Prof.ssa Laura De Marinis

Coordinatore Scientifico del Master Universitario di II Livello in diagnosi e terapia delle patologie ipotalamo ipofisarie - Università Cattolica del Sacro Cuore, Roma

SEGRETERIA SCIENTIFICA

Coordinatori: Dott. Antonio Bianchi, Dott.ssa Antonella Giampietro

Massimiliano Andrioli
Chiara Bima

Sabrina Chiloiro
Giuseppe Grande

Domenico Milardi
Marilda Mormando

Serena Piacentini
Linda Tartaglione

U.O.S. di Patologia Ipotalamo – Ipofisaria, Policlinico Universitario A. Gemelli, Roma

SEDE

Hotel Donna Camilla Savelli

Via Garibaldi, 27 - Roma - Tel. 06 588861

ECM 680 - 275782

L'evento rientra nel piano formativo ECM 2019 della DOTCOM s.r.l. ed è rivolto alle figure professionali di **Infermiere** e di **Medico - Chirurgo** per le seguenti discipline: Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia, Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurochirurgia, Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnostica, Radioterapia.

Assegnati n. 12 Crediti Formativi ECM

PRE-ISCRIZIONE

L'iscrizione è gratuita e potrà essere effettuata inviando un email al seguente indirizzo: info@dotcomeventi.com. L'accesso in aula è riservato ai primi 100 partecipanti. Si ricorda che l'attestazione dei crediti ottenuti è subordinata alla partecipazione del 90% della durata dei lavori, alla compilazione della scheda di valutazione dell'evento e al superamento della prova di apprendimento (questionario, almeno 75% risposte esatte).

OBIETTIVO FORMATIVO

Documentazione Clinica. Percorsi Clinico-Assistenziali Diagnostici e Riabilitativi, Profili di Assistenza - Profili di Cura

PROVIDER E SEGRETERIA ORGANIZZATIVA



Via Flaminia, 54 | 00196 Roma

Tel. 06 4061370 | Fax 06 3242600 | E-Mail: info@dotcomeventi.com | www.dotcomeventi.com

Lingue ufficiali: Italiano/Inglese

Con la sponsorizzazione non condizionante di



Update on the biological and molecular mechanisms in Pit-NET and their relationship with the personalized therapy

ROME
28th 29th
November **2019**
Hotel Donna Camilla Savelli

Con il Patrocinio di



UNIVERSITÀ
CATTOLICA
del Sacro Cuore

Gemelli



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

Responsabile Scientifico
Laura De Marinis

1st DAY | **Thursday, 28th** November 2019

12.30 *Welcome Light Lunch*
Registration

13.30 Introduction: **L. De Marinis**

Welcome Speech: **R. Bellantone, G. Carpani, A. Lenzi, A. Olivi, G. Paludetti, A. Pontecorvi, P. Pozzilli, G. Scambia, A. Scoppola**

14.00 Treatment challenges and the doctor-patient relationship - **L. Festa (ANIPI)**

PRESIDENTIAL LECTURE
Chairman: **A. Pontecorvi**

14.10 European Community policies in endocrine and metabolic diseases - **A. Giustina**

14.50 The Pituitary Tumor Centers of Excellence - **F. Casanueva**

I SESSION - New genetic knowledge and acquisitions on PitNETs
Chairmen: **E. De Menis, M. L. Jaffrain-Rea, M. Zollino**

15.30 ACTH secreting pituitary tumors: from adenoma to carcinoma – **S. Cannavò**

15.50 Somatic and germline changes in pituitary neuroendocrine tumours, PitNETs - **M. Korbonits**

16.10 *Coffee Break*

16.30 The genetic basis of Pit-NETs among the endocrine syndromes - **E. D. Capoluongo**

16.50 New approaches in the medical treatment of GH secreting PitNET: rule of the regulators of the cell metabolism - **M. C. Zatelli**

17.10 Discussion

II SESSION - DEBATE
Chairmen: **S. Grottoli, A. G. A. Lania**

17.30 The impact of the pathological assessment of PitNET on the management of affected patients: Pros and cons - **A. Bianchi, D. Ferone**

18.30 Conclusions

2nd DAY | **Friday, 29th** November 2019

08.00 Registration

LECTURE
Chairmen: **V. Toscano, P. Zuppi**

08.30 New knowledges on hormonal replacement therapy of growth hormone deficit in PitNET - **A. Giampietro**

III SESSION - New pathological knowledges and acquisitions on PitNETs
Chairmen: **G. Rindi, C. Scaroni**

09.00 Sex-related differences and clinical, pathological and molecular factors of aggressiveness of lactotroph tumours - **J. Trouillas**

09.30 Criteria and controversies of the microscopic classification of pituitary neuroendocrine tumours: are transcription factors the answer? **F. Roncaroli**

10.00 How the new biological and molecular knowledges may impact on the medical management of PitNET? - **G. Mantovani**

10.30 Discussion

10.45 *Coffee Break*

LECTURE
Chairmen: **G. Arnaldi, A. Fabbri**

11.00 How the meta-analysis may impact on the medical management of GH secreting PitNET? **A. M. Isidori**

11.20 How to Position Pegvisomant and Pasireotide LAR Treatment in Acromegaly? **E. C. Coopmans**

IV SESSION - New genetic and molecular knowledges in the multidisciplinary approach of PitNET in Pituitary Tumor Centers of Excellence
Chairmen: **M. V. Davì, V. Rufini**

11.40 Role of the expert in osteoporosis - **S. Frara, A. Spada**

12.00 Role of the expert in neuroradiology - **T. Tartaglione**

12.20 Role of the expert in radiotherapy - **S. Chiesa, G. Minniti**

12.40 Role of the expert in translational medicine - **F. Gatto**

13.00 Role of the expert in pituitary pathology - **M. Gessi**

13.20 Discussion

13.40 *Light Lunch*

V SESSION - How the new biological and molecular knowledges may impact on the neuro-surgical management of PitNET?
Chairmen: **C. Anile, A. Olivi**

14.40 The experts in neurosurgery - **F. Doglietto, L. Lauretti**

15.20 The expert in otorinolaringoiatry - **M. Rigante**

15.40 Discussion

VI SESSION: How the new biological and molecular knowledges may impact on the medical therapies of PitNET?
Chairmen: **R. Baldelli, M. Poggi**

15.50 ACTH secreting PitNET - **R. Pivonello**

16.10 GH secreting PitNET - **S. Chiloiro**

16.30 Not secreting PitNET - **P. Maffei**

16.50 Prolactin secreting PitNET - **C. Bima**

17.10 Discussion

17.30 CME evaluation

Carmelo Anile, Roma
Giorgio Arnaldi, Ancona
Roberto Baldelli, Roma
Rocco Bellantone, Roma
Antonio Bianchi, Roma
Chiara Bima, Torino
Salvatore Cannavò, Messina
Ettore Domenico Capoluongo, Roma
Guido Carpani, Roma
Felipe Casanueva, Santiago De Compostela
Silvia Chiesa, Roma
Sabrina Chiloiro, Roma
Eva C. Coopmans, Rotterdam
Maria Vittoria Davì, Verona
Laura De Marinis, Roma
Ernesto De Menis, Treviso
Francesco Doglietto, Brescia
Andrea Fabbri, Roma

Diego Ferone, Genova
Lucia Festa, Roma
Stefano Frara, Milano
Federico Gatto, Genova
Marco Gessi, Roma
Antonella Giampietro, Roma
Andrea Giustina, Milano
Silvia Grottoli, Torino
Andrea Marcello Isidori, Roma
Marie Lise Jaffrain – Rea, LAquila
Marta Korbonits, London
Andrea Gerardo Antonio Lania, Milano
Liverana Lauretti, Roma
Pietro Maffei, Padova
Giovanna Mantovani, Milano
Giuseppe Minniti, Roma
Alessandro Olivi, Roma
Gaetano Paludetti, Roma

Rosario Pivonello, Napoli
Maurizio Poggi, Roma
Alfredo Pontecorvi, Roma
Mario Rigante, Roma
Guido Rindi, Roma
Federico Roncaroli, Manchester
Vittoria Rufini, Roma
Carla Scaroni, Padova
Alessandro Scoppola, Roma
Antonio Spada, Roma
Tommaso Tartaglione, Roma
Vincenzo Toscano, Roma
Jacqueline Trouillas, Lione
Maria Chiara Zatelli, Ferrara
Marcella Zollino, Roma
Paolo Zuppi, Roma

FACULTY